Roche’s breast cancer drug candidate, giredestrant, showed improved invasive disease-free survival in early-stage patients. Shares rose 10% on Nov 18. The drug is the first in its class to succeed in this patient population. Data from the lidERA trial could impact sales projections. Other similar drugs are in development by competitors.

Roche is maintaining a fair value estimate for giredestrant, indicating a higher likelihood of differentiation. Sales projections for 2034 are around CHF 1.5 billion. Competitors like Lilly and AstraZeneca also have selective estrogen receptor degraders in development. AstraZeneca’s upcoming data in 2026 could impact sales assumptions for giredestrant.

Morningstar’s analysis highlights Roche’s position in the market and the potential of giredestrant. The drug’s success in early-stage patients could impact its growth trajectory. Competitors’ developments could also influence sales projections for Roche’s drug.

Read more at Morningstar: Roche: Data for Breast Cancer Drug Candidate Giredestrant Support Potential Differentiated Status